Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PAM | P19021 | 2/20 | 0.42 |
| ▸ | POLM | Q9NP87 | 1/20 | 0.42 |
| ▸ | POLK | Q9UBT6 | 1/20 | 0.42 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.42 |
| ▸ | POLH | Q9Y253 | 1/20 | 0.42 |
| ▸ | TOP2A | P11388 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15236082 | 1.00 | DGKA (0.46) | DGKAALOX15LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL28506184 | 0.98 | ALOX15 (0.46) | DGKAALOX15LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL1998098 | 0.93 | KMT2A (0.44) | DGKAALOX15KMT2ASMN1; SMN2 | |
| SCHEMBL17373963 | 0.91 | VCAM1 (0.38) | ALOX15LMNAKMT2AMAPT | |
| SCHEMBL17337902 | 0.88 | KMT2A (0.40) | LMNAKMT2AMAPTMAPK1TSHR | |
| SCHEMBL23813735 | 0.87 | PAOX (0.41) | ALOX15KMT2AMAPT | |
| SCHEMBL27050874 | 0.87 | VCAM1 (0.46) | ALOX15KMT2ASMN1; SMN2MAPT | |
| SCHEMBL27050860 | 0.87 | VCAM1 (0.46) | ALOX15KMT2ASMN1; SMN2MAPT | |
| SCHEMBL22271695 | 0.86 | DGKA (0.52) | DGKAALOX15LMNAKMT2APAM | |
| SCHEMBL22463686 | 0.86 | DGKA (0.52) | DGKAALOX15LMNAKMT2APAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118459539-A | Compounds for modulating training immunity and methods of use thereof | 生物治疗探索股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| US-20240190921-A1 | COMPOUNDS FOR REGULATING TRAINED IMMUNITY, AND THEIR METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2024-06-13 | — | — | US | disclosed |
| CN-117355298-A | Compounds for modulating training immunity and methods of use thereof | 生物治疗探索股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190921-A1 | COMPOUNDS FOR REGULATING TRAINED IMMUNITY, AND THEIR METHODS OF USE | MYD88, CD74, IRF3 | DGKA 711/4885ALOX15 159/4885LMNA 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.